Harpoon Therapeutics (HARP) Received its Third Buy in a Row
After Piper Sandler and H.C. Wainwright gave Harpoon Therapeutics (NASDAQ: HARP) a Buy rating last month, the company received another Buy, this time from Robert W. Baird. Analyst Colleen M. Kusy maintained a Buy rating on Harpoon Therapeutics yesterday and set a price target of $35.00. The company’s shares closed last Monday at $15.27.
According to TipRanks.com, Kusy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.7% and a 30.0% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Iovance Biotherapeutics, and Apellis Pharmaceuticals.
Currently, the analyst consensus on Harpoon Therapeutics is a Strong Buy with an average price target of $33.00, representing a 104.7% upside. In a report issued on May 28, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $40.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.24 and a one-year low of $10.55. Currently, Harpoon Therapeutics has an average volume of 247.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.